Biological characteristics and prognostic analysis of stage Ⅰ uterine serous carcinoma

王登凤,彭春蓉,刘欣,张国楠
DOI: https://doi.org/10.3760/cma.j.cn101548-20200914-00141
2020-01-01
Abstract:Objective:To investigate the prognostic factors of stage Ⅰ uterine serous carcinoma (USC), and help to plan the postoperative adjuvant treatment.Methods:We retrospectively analyzed the clinicopathological features, treatment and prognosis of stage Ⅰ USC patients in our hospital between 2009 and 2018.Results:A total of 67 patients were enrolled and 56 cases were followed up. 36 cases (64.3%) were in stage Ⅰ A, and 20 cases (35.7%) were in stage Ⅰ B; 21 cases (37.5%)were USC, and 35 cases (62.5%) were mixed carcinoma with USC. The median follow-up time was 132.7 months. 6 patients had recurrence, and 5 patients died. There were statistically significant differences in FIGO stage, tumor grade, depth of myometrial invasion, height and weight between recurrence group and non-recurrence group ( P<0.05); in stage Ⅰ B, there were significant differences in postoperative adjuvant therapy, CA125 value before treatment, height and weight between recurrence group and non-recurrence group ( P<0.05). Univariate analysis showed that height, weight, body mass index (BMI) and CA125 value before treatment were correlated with prognosis( P<0.05). Conclusions:USC is highly malignant in biological behavior, so even for stage Ⅰ A patients, we suggest postoperative chemotherapy to prevent distant metastasis, and the benefit of radiotherapy is still controversial; for stage IB, chemotherapy combined with radiotherapy may reduce the recurrence rate. Small body size and CA125>43 U/ml before treatment are associated with worse prognosis, so they may be used as risk factors for early stage of USC to guide the postoperative adjuvant treatment.
What problem does this paper attempt to address?